Susana Del Toro-Arreola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9154201/publications.pdf

Version: 2024-02-01

9 papers 284 citations

7 h-index 9 g-index

9 all docs 9 docs citations 9 times ranked 509 citing authors

#	Article	IF	CITATIONS
1	Gut microbiota from Mexican patients with metabolic syndrome and HIV infection: An inflammatory profile. Journal of Applied Microbiology, 2022, 132, 3839-3852.	3.1	6
2	Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis. Clinical and Experimental Immunology, 2021, 204, 78-95.	2.6	10
3	Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy. Journal of Controlled Release, 2021, 334, 389-412.	9.9	26
4	B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines. BMC Cancer, 2020, 20, 1083.	2.6	10
5	Anti-fouling SERS-based immunosensor for point-of-care detection of the B7–H6 tumor biomarker in cervical cancer patient serum. Analytica Chimica Acta, 2020, 1138, 110-122.	5.4	38
6	Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer. BMC Immunology, 2020, 21, 9.	2.2	13
7	NK cells at the crossroads in COVID-19: a question of timing. Ciencia, TecnologÃa Y Salud, 2020, 7, 309-324.	0.1	1
8	Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy. Immunobiology, 2018, 223, 57-63.	1.9	16
9	Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer, 2009, 9, 186.	2.6	164